Daily Ards Research Analysis
Mechanistic work identifies ferroptosis and oxidative-stress pathways—particularly Nrf2 signaling—as actionable nodes in ARDS, with a plant-derived lignan (liriodendrin) showing multi-target protection in an LPS mouse model. Complementary evidence synthesizes natural-product modulation of inflammatory/oxidative pathways in viral pneumonia and characterizes antibody kinetics in hospitalized COVID-19 patients, linking serologic patterns to ARDS severity.
Summary
Mechanistic work identifies ferroptosis and oxidative-stress pathways—particularly Nrf2 signaling—as actionable nodes in ARDS, with a plant-derived lignan (liriodendrin) showing multi-target protection in an LPS mouse model. Complementary evidence synthesizes natural-product modulation of inflammatory/oxidative pathways in viral pneumonia and characterizes antibody kinetics in hospitalized COVID-19 patients, linking serologic patterns to ARDS severity.
Research Themes
- Ferroptosis and oxidative-stress regulation in ARDS
- Natural-product modulation of NF-κB/Nrf2/PI3K-Akt/MAPK/NLRP3 pathways
- Serologic kinetics linked to ARDS severity in COVID-19
Selected Articles
1. Protective Effects of Liriodendrin Against Oxidative Stress and Ferroptosis in a Mouse Model of Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome.
In LPS-induced ARDS mice, liriodendrin reduced histopathologic lung injury and lipid peroxidation, restored antioxidant enzyme activities, upregulated ferroptosis-related proteins, and increased Nrf2 phosphorylation in a dose-dependent manner. Findings position ferroptosis/Nrf2 modulation as a promising therapeutic avenue.
Impact: This is among the first in vivo demonstrations that a specific natural product can concurrently modulate oxidative stress and ferroptosis via Nrf2 signaling in ARDS. It provides targetable mechanisms and a candidate compound.
Clinical Implications: Suggests ferroptosis and Nrf2 pathways as druggable targets in ARDS; liriodendrin merits translational evaluation (dosing, timing, safety) as adjunctive therapy.
Key Findings
- Dose-dependent reduction of lung histopathologic injury after LPS challenge
- Decreased lipid peroxidation with restoration of SOD, catalase, and GPx activities
- Upregulation of HO-1, SLC7A11, and GPX4 expression
- Enhanced phosphorylation of Nrf2 indicating activation of antioxidant defense
- Protective effects comparable to a steroid comparator (dexamethasone pre-treatment context)
Methodological Strengths
- Multiple orthogonal endpoints (histology, lipid peroxidation, enzyme activities, protein expression, signaling)
- Dose–response evaluation with active comparator (dexamethasone) pre-treatment
Limitations
- Pre-treatment design in a single LPS model limits clinical translatability to established ARDS
- No survival or long-term functional outcomes; pharmacokinetics/toxicity not addressed
Future Directions: Test post-injury dosing across ARDS models (e.g., bacterial/viral, ventilator-induced), delineate direct ferroptosis dependence (e.g., genetic/chemical inhibition), and perform PK/safety studies for translation.
Liriodendrin, a bioactive lignan diglucoside derived from several medicinal plants, has been demonstrated to exhibit pharmacological activities, such as antioxidative and anti-inflammatory activities. Up to now, no evidence has shown that acute respiratory distress syndrome (ARDS) is improved by liriodendrin. This study was conducted to investigate the protective effects of liriodendrin against oxidative stress and ferroptosis, key mechanisms underlying the pathogenesis of ARDS, in a mouse model of lipopolysaccharide (LPS)-induced ARDS. To investigate the potential of liriodendrin to mitigate oxidative stress and inhibit ferroptosis, adult BALB/c male mice with LPS-induced ARDS were treated with varying concentrations of liriodendrin. Mice received liriodendrin or dexamethasone before LPS administration. The effects of liriodendrin were evaluated by measuring changes in pulmonary histopathology, levels of lipid peroxidation, activities of antioxidative enzymes (superoxide dismutase, catalase, glutathione peroxidase), and expression of ferroptosis-related proteins (heme oxygenase-1, cystine/glutamate antiporter SLC7A11, glutathione peroxidase-4). In addition, we measured the phosphorylation of nuclear factor erythroid 2-related factor 2 (Nrf-2), a critical regulator of cellular defense mechanisms against oxidative damage. The results indicated that liriodendrin substantially suppressed histopathological damage, reduced lipid peroxidation, and restored antioxidative enzyme activity in a dose-dependent manner. Furthermore, this compound markedly upregulated the expression of ferroptosis-related proteins and promoted the phosphorylation of Nrf-2. Our findings suggest that liriodendrin protects against LPS-induced ARDS by regulating oxidative stress and ferroptosis. The ability of liriodendrin to modulate both antioxidative responses and ferroptosis markers through Nrf-2 phosphorylation highlights its potential as a therapeutic agent in the treatment of ARDS.
2. Natural products alleviate viral pneumonia by modulating inflammatory and oxidative-stress pathways.
This review synthesizes evidence that natural products (e.g., flavonoids, polyphenols, polysaccharides, terpenoids) attenuate viral-pneumonia inflammation and oxidative stress by modulating NF-κB, Nrf2, PI3K/Akt, MAPK, and NLRP3 pathways. It provides a mechanistic framework for multi-target adjunctive therapies potentially relevant to ARDS prevention and mitigation.
Impact: By unifying mechanistic insights across pathways central to viral lung injury, the review charts translatable targets and candidate compound classes for future trials.
Clinical Implications: Supports rational design of adjunctive anti-inflammatory/antioxidant regimens using natural products; highlights need for standardized formulations and RCTs in viral pneumonia at risk of ARDS.
Key Findings
- Natural compounds modulate NF-κB, Nrf2, PI3K/Akt, MAPK, and NLRP3 inflammasome pathways
- Actions include cytokine-storm suppression, ROS reduction, and preservation of alveolar-epithelial integrity
- Literature search across PubMed, Web of Science, and SciFinder focusing on the last decade
Methodological Strengths
- Multi-database literature search with mechanism-focused keywords
- Pathway-centered synthesis linking compound classes to immune and redox modulation
Limitations
- Not a PRISMA-compliant quantitative meta-analysis; potential selection/publication bias
- Predominantly preclinical evidence; clinical efficacy and dosing remain uncertain
Future Directions: Standardize extracts/formulations, define pharmacokinetics, and test prioritized candidates in phase I/II RCTs in viral pneumonia populations at risk for ARDS.
Viral pneumonia, primarily caused by influenza viruses, coronaviruses, and other respiratory pathogens, is characterized by direct alveolar epithelial injury and an excessive immune response, leading to severe inflammation, oxidative stress, and, in critical cases, acute respiratory distress syndrome and multi-organ failure. Traditional Chinese Medicine (TCM), widely employed in China for both the prevention and treatment of viral pneumonia, provides multitarget and broad-spectrum therapeutic benefits with low toxicity and minimal side effects, offering a promising alternative to conventional antiviral therapies. Recent studies have demonstrated that natural products derived from TCM, including flavonoids, polyphenols, polysaccharides, and terpenoids, can effectively modulate immune and oxidative stress responses by targeting multiple signaling pathways. In this review, we conducted a systematic literature search in PubMed, Web of Science, and SciFinder databases, focusing primarily on studies published over the past decade. Keyword combinations included "viral pneumonia," "Traditional Chinese Medicine," "natural products," "inflammation," and "oxidative stress," in addition to mechanism-related terms such as "NF-κB," "Nrf2," "PI3K/Akt," "MAPK," and "NLRP3 inflammasome." Natural compounds acting on these pathways have been shown to suppress cytokine storms, reduce reactive oxygen species accumulation, preserve alveolar epithelial integrity, and alleviate pulmonary inflammation. This review highlights the latest progress in understanding how natural products exert protective effects in viral pneumonia through the modulation of inflammation and oxidative stress-related pathways. These findings provide a theoretical foundation for developing novel anti-inflammatory and antioxidant therapeutic strategies based on natural medicines for the treatment of viral respiratory diseases.
3. Kinetics of anti-SARS-CoV-2 antibodies and hematological parameters in hospitalized pre-vaccination COVID-19 patients in Peru.
Among 44 hospitalized, pre-vaccination COVID-19 patients in Peru (157 samples), anti-SARS-CoV-2 IgG stabilized by hospital days 10–15 while IgM declined after day 10. Antibody variability was greater in severe ARDS, and IgG levels positively correlated with lymphocyte counts.
Impact: Provides time-resolved antibody kinetics linked to ARDS severity in a Latin American cohort, informing timing of serology and potential prognostic markers.
Clinical Implications: Supports interpreting serology by hospital day (IgG stabilization around days 10–15; IgM decline after day 10) and considering lymphocyte–IgG relationships when assessing severe ARDS risk.
Key Findings
- IgG levels stabilized between hospital days 10–15; IgM levels declined after day 10
- Greater antibody variability observed in severe ARDS cases
- Positive correlation between IgG levels and lymphocyte counts
Methodological Strengths
- Serial sampling (157 samples from 44 patients) enabling kinetic analyses
- Use of recombinant S1 and RBD in in-house ELISAs with multiple statistical approaches (regression, KM, ROC)
Limitations
- Single-center, small cohort from early pandemic; generalizability limited
- In-house assay may limit external comparability; pre-vaccination era only
Future Directions: Validate kinetics and prognostic associations in larger, multicenter cohorts with standardized assays and include vaccinated populations and viral variants.
BACKGROUND: The COVID-19 pandemic exposed vulnerabilities in health systems and revealed variations in immune responses across populations worldwide. This study examined the kinetics of IgG and IgM antibodies against S1 and receptor-binding domain (RBD) proteins in hospitalized Peruvian patients prior to vaccination. METHOD: A total of 157 serological samples were collected from 44 hospitalized COVID-19 patients during Peru's first wave (August-October 2020) and stored at -80 °C. Anti-SARS-CoV-2 IgG and IgM antibodies were quantified using an in-house ELISA with recombinant Spike S1 and RBD proteins. Statistical analyses-including linear regression, Kaplan-Meier curves, and receiver operating characteristic (ROC) curves-were conducted to evaluate antibody kinetics, clinical correlations, and predictive accuracy. RESULTS: IgG levels stabilized between days 10 and 15 of hospitalization, while IgM levels declined after day 10, with greater variability observed in severe acute respiratory distress syndrome (ARDS) cases. A significant positive correlation was found between IgG levels and lymphocyte counts (